2024
Moving Beyond Devices to Patient Selection A New Frontier in Stroke Prevention After TAVR
Ahmad Y, Lansky A. Moving Beyond Devices to Patient Selection A New Frontier in Stroke Prevention After TAVR. JACC Cardiovascular Interventions 2024, 17: 1691-1692. PMID: 39048256, DOI: 10.1016/j.jcin.2024.06.017.Peer-Reviewed Original Research
2023
Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study
Grubman D, Ahmad Y, Leipsic J, Blanke P, Pasupati S, Webster M, Nazif T, Parise H, Lansky A. Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study. The American Journal Of Cardiology 2023, 207: 28-34. PMID: 37722198, DOI: 10.1016/j.amjcard.2023.08.137.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementAtrial fibrillationHuman studiesEmbolic protection device useHigh embolic riskPrimary end pointHigh-risk patientsIndependent core laboratorySelf-expanding valvesComputed tomography angiographyProtection device useCerebral embolizationCerebrovascular eventsEmbolic riskAcute thrombusEmbolic burdenAngiography featuresTechnical successTomography angiographyEmbolic debrisValve useCore laboratoryEnd pointEffect of antecedent statin usage on conduction disturbances and arrhythmias after transcatheter aortic valve replacement
Shah T, Maarek R, See C, Huang H, Wang Y, Parise H, Forrest J, Lansky A. Effect of antecedent statin usage on conduction disturbances and arrhythmias after transcatheter aortic valve replacement. Cardiovascular Revascularization Medicine 2023, 59: 3-8. PMID: 37573173, DOI: 10.1016/j.carrev.2023.07.022.Peer-Reviewed Original ResearchConceptsAtrial fibrillationConduction disturbancesPrimary endpointStatin usersPacemaker placementRate of AFTranscatheter aortic valve replacementNew atrial fibrillationNew conduction disturbancesPersistent conduction disturbancesAortic valve replacementLong-term prognosisSmall retrospective studiesSignificant differencesPrior pacemakerIndex hospitalizationIntensity statinsValve replacementConsecutive patientsPropensity matchingProcedural complicationsStatin regimenRetrospective studyStatin usageCardiac proceduresSex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention Insights From the PROTECT III Study
Shah T, Abu-Much A, Batchelor W, Grines C, Baron S, Zhou Z, Li Y, Maini A, Redfors B, Hussain Y, Wollmuth J, Basir M, O'Neill W, Lansky A. Sex Differences in pLVAD-Assisted High-Risk Percutaneous Coronary Intervention Insights From the PROTECT III Study. JACC Cardiovascular Interventions 2023, 16: 1721-1729. PMID: 37409991, DOI: 10.1016/j.jcin.2023.04.036.Peer-Reviewed Original ResearchConceptsHigh-risk percutaneous coronary interventionFemale patientsIII studySex-based differencesImmediate PCISYNTAX scoreClinical outcomesMyocardial infarctionStroke/transient ischemic attackWorse renal functionAcute limb ischemiaTransient ischemic attackSex differencesPercutaneous coronary interventionAcute myocardial infarctionHigher ejection fractionCause deathCoronary complicationsIschemic attackMajor bleedingNonfemoral accessPercutaneous CoronaryPrior strokeCerebrovascular eventsVascular complicationsImpact of New-Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single-Center Study
See C, Wang Y, Huang H, Parise H, Yang Y, Tirziu D, Francese D, Papoutsidakis N, Bader E, Kaple R, Cleman M, Lansky A, Forrest J. Impact of New-Onset Conduction Disturbances following Transcatheter Aortic Valve Replacement on Outcomes: A Single-Center Study. Journal Of Interventional Cardiology 2023, 2023: 5390338. PMID: 37292113, PMCID: PMC10247319, DOI: 10.1155/2023/5390338.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementNew-onset conduction disturbancesAortic valve replacementPersistent conduction disturbancesConduction disturbancesValve replacementSurgical aortic valve replacementSingle-center retrospective analysisYale-New Haven HospitalSingle-center studyCause mortality ratesCause mortality riskLong-term outcomesNew Haven HospitalPeriprocedural factorsAortic stenosisConsecutive patientsTAVR proceduresTerm outcomesRetrospective analysisMortality riskMortality ratePatientsOutcomesPatient's ECGPublic Reporting of Stroke After Transcatheter Aortic Valve Replacement A Cautionary Tale ∗
Lansky A, Ahmad Y. Public Reporting of Stroke After Transcatheter Aortic Valve Replacement A Cautionary Tale ∗. JACC Cardiovascular Interventions 2023, 16: 177-178. PMID: 36697153, DOI: 10.1016/j.jcin.2022.11.010.Peer-Reviewed Original Research
2022
Depression and Perceived Stress After Spontaneous Coronary Artery Dissection and Comparison With Other Acute Myocardial Infarction (the VIRGO Experience)
Murugiah K, Chen L, Dreyer RP, Bouras G, Safdar B, Lu Y, Spatz ES, Gupta A, Khera R, Ng VG, Bueno H, Tweet MS, Spertus JA, Hayes SN, Lansky A, Krumholz HM. Depression and Perceived Stress After Spontaneous Coronary Artery Dissection and Comparison With Other Acute Myocardial Infarction (the VIRGO Experience). The American Journal Of Cardiology 2022, 173: 33-38. PMID: 35365290, PMCID: PMC9133198, DOI: 10.1016/j.amjcard.2022.03.005.Peer-Reviewed Original ResearchConceptsSpontaneous coronary artery dissectionPatient Health Questionnaire-9Coronary artery dissectionPSS-14 scoreArtery dissectionBaseline PHQ-9 scoreAcute myocardial infarction patientsCardiovascular risk factorsPHQ-9 scoresAcute myocardial infarctionMyocardial infarction patientsYears of agePerceived Stress Scale scoresStress Scale scoresLinear mixed-effects analysisSCAD casesVIRGO StudyQuestionnaire-9Infarction patientsMixed-effects analysisMyocardial infarctionSubgroup analysisRisk factorsRoutine screeningClinical acuityST-Segment Elevation Myocardial Infarction: Sex Differences in Incidence, Etiology, Treatment, and Outcomes
Shah T, Kapadia S, Lansky AJ, Grines CL. ST-Segment Elevation Myocardial Infarction: Sex Differences in Incidence, Etiology, Treatment, and Outcomes. Current Cardiology Reports 2022, 24: 529-540. PMID: 35286662, DOI: 10.1007/s11886-022-01676-7.Peer-Reviewed Original ResearchConceptsST-elevation myocardial infarctionMyocardial infarctionMechanical circulatory supportStandard of careSex-based disparitiesEvidence-based strategiesEarly revascularizationCirculatory supportPoor outcomeWorse outcomesYoung womenStandardized protocolWomenOutcomesInfarctionTreatmentEtiologySex differencesHeterogeneous entityRevascularizationPatientsDisparitiesPurposeAlthoughIncidence
2021
Coronary Revascularization in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis
Patel KP, Michail M, Treibel TA, Rathod K, Jones DA, Ozkor M, Kennon S, Forrest JK, Mathur A, Mullen MJ, Lansky A, Baumbach A. Coronary Revascularization in Patients Undergoing Aortic Valve Replacement for Severe Aortic Stenosis. JACC Cardiovascular Interventions 2021, 14: 2083-2096. PMID: 34620388, DOI: 10.1016/j.jcin.2021.07.058.Peer-Reviewed Original ResearchConceptsAortic valve replacementCoronary artery diseaseAortic stenosisHemodynamic statusCoronary revascularizationValve replacementAssessment of CADPatients Undergoing Aortic Valve ReplacementConcomitant coronary artery diseaseImpact of ASSignificant coronary artery diseaseConcomitant aortic stenosisRole of revascularizationSevere aortic stenosisThird of patientsCohort of patientsDual pathologyArtery diseaseTherapeutic challengeCertain patientsMyocardial ischemiaCoronary assessmentPatientsRevascularizationMultidisciplinary teamLong term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials
Hussain Y, Gaston S, Kluger J, Shah T, Yang Y, Tirziu D, Lansky A. Long term outcomes of ultrathin versus standard thickness second‐generation drug eluting stents: Meta‐analysis of randomized trials. Catheterization And Cardiovascular Interventions 2021, 99: 563-574. PMID: 34236755, DOI: 10.1002/ccd.29866.Peer-Reviewed Original ResearchConceptsSecond generation drug eluting stentsTarget lesion failureDrug eluting stentsLong-term outcomesEluting stentsTerm outcomesRisk ratioIschemia-driven target vessel revascularizationTarget vessel myocardial infarctionLong-term clinical outcomesProbable stent thrombosisTarget vessel revascularizationTerm clinical outcomesVessel myocardial infarctionPercutaneous coronary interventionCoronary artery diseaseConfidence intervalsFirst generation drug eluting stentsRandom-effects modelLesion failureVessel revascularizationCoronary interventionSecondary outcomesArtery diseaseCardiac deathOutcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention
O'Neill BP, Grines C, Moses JW, Ohman EM, Lansky A, Popma J, Kapur NK, Schreiber T, Mannino S, O'Neill WW, Medjamia AM, Mahmud E. Outcomes of bailout percutaneous ventricular assist device versus prophylactic strategy in patients undergoing nonemergent percutaneous coronary intervention. Catheterization And Cardiovascular Interventions 2021, 98: e501-e512. PMID: 34051033, DOI: 10.1002/ccd.29758.Peer-Reviewed Original ResearchConceptsPercutaneous ventricular assist deviceNonemergent percutaneous coronary interventionPercutaneous coronary interventionHemodynamic collapseVentricular assist deviceCoronary interventionProphylactic supportImpella percutaneous ventricular assist deviceAssist deviceOutcomes of patientsVentricular ejection fractionHospital mortalityHospital outcomesEjection fractionHeart failureMedian baselinePVAD supportProphylactic strategiesFemale genderStudy populationLow prevalencePatientsMain diseaseOutcomesMortalityA randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial
Lansky AJ, Makkar R, Nazif T, Messé S, Forrest J, Sharma R, Schofer J, Linke A, Brown D, Dhoble A, Horwitz P, Zang M, DeMarco F, Rajagopal V, Dwyer MG, Zivadinov R, Stella P, Rovin J, Parise H, Kodali S, Baumbach A, Moses J. A randomized evaluation of the TriGuard™ HDH cerebral embolic protection device to Reduce the Impact of Cerebral Embolic LEsions after TransCatheter Aortic Valve ImplanTation: the REFLECT I trial. European Heart Journal 2021, 42: 2670-2679. PMID: 34000004, DOI: 10.1093/eurheartj/ehab213.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementEfficacy endpointCerebral embolic protection devicesTranscatheter aortic valve implantationCentral nervous system injuryCerebral embolic lesionsCerebral ischemic lesionsHealth Stroke ScalePrimary efficacy endpointPrimary safety outcomeAortic valve replacementAortic valve implantationEmbolic protection devicesNervous system injuryDiffusion-weighted magnetic resonanceMontreal Cognitive AssessmentEffectiveness endpointCause mortalityCerebral protectionSafety endpointStroke ScaleValve implantationValve replacementI trialIschemic lesionsRandomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement REFLECT II
Nazif TM, Moses J, Sharma R, Dhoble A, Rovin J, Brown D, Horwitz P, Makkar R, Stoler R, Forrest J, Messé S, Dickerman S, Brennan J, Zivadinov R, Dwyer MG, Lansky AJ, Investigators R. Randomized Evaluation of TriGuard 3 Cerebral Embolic Protection After Transcatheter Aortic Valve Replacement REFLECT II. JACC Cardiovascular Interventions 2021, 14: 515-527. PMID: 33663779, DOI: 10.1016/j.jcin.2020.11.011.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementSafety endpointValve replacementProcedure-related ischemic strokeCerebral embolic protectionComposite efficacy endpointPrimary safety endpointCerebral embolizationCerebral protectionEfficacy endpointII trialCerebral injuryIschemic strokeEmbolic protectionPatientsDrug AdministrationUS sitesU.S. FoodEndpointData reviewTrialsMulticenterEmbolizationInjury
2020
Revascularization Options for Females With Multivessel Coronary Artery Disease A Meta-Analysis of Randomized Controlled Trials
Gul B, Shah T, Head SJ, Chieffo A, Hu X, Li F, Brackett A, Gesick C, Bisarya PK, Lansky A. Revascularization Options for Females With Multivessel Coronary Artery Disease A Meta-Analysis of Randomized Controlled Trials. JACC Cardiovascular Interventions 2020, 13: 1009-1010. PMID: 32113933, DOI: 10.1016/j.jcin.2019.12.036.Peer-Reviewed Original Research
2019
First-in-Human Study of Paclitaxel Drug-Coated Chocolate Coronary Percutaneous Transluminal Coronary Angioplasty Balloon Catheter in De Novo Coronary Artery Lesions
Garcia-Lithgow C, Tirziu D, Zhou S, Bouras G, Shah T, Grubman D, Javier JJ, Mustapha JA, Abizaid A, Lansky AJ. First-in-Human Study of Paclitaxel Drug-Coated Chocolate Coronary Percutaneous Transluminal Coronary Angioplasty Balloon Catheter in De Novo Coronary Artery Lesions. JACC Cardiovascular Interventions 2019, 12: 2568-2570. PMID: 31857033, DOI: 10.1016/j.jcin.2019.08.044.Peer-Reviewed Original ResearchTreating Post-Angioplasty Dissection in the Femoropopliteal Arteries Using the Tack Endovascular System 12-Month Results From the TOBA II Study
Gray WA, Cardenas JA, Brodmann M, Werner M, Bernardo NI, George JC, Lansky A. Treating Post-Angioplasty Dissection in the Femoropopliteal Arteries Using the Tack Endovascular System 12-Month Results From the TOBA II Study. JACC Cardiovascular Interventions 2019, 12: 2375-2384. PMID: 31806218, DOI: 10.1016/j.jcin.2019.08.005.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, BalloonBlood Vessel ProsthesisBlood Vessel Prosthesis ImplantationEuropeFemaleFemoral ArteryHumansMaleMiddle AgedPeripheral Arterial DiseasePopliteal ArteryProspective StudiesProsthesis DesignRisk FactorsStentsTime FactorsTreatment OutcomeUnited StatesVascular Access DevicesVascular PatencyVascular System InjuriesConceptsProximal popliteal arteryDrug-coated balloonsSuperficial femoral arteryPlain balloonPopliteal arteryFemoral arteryTack Endovascular SystemLong-term outcomesDCB angioplastyEfficacy endpointPrimary patencyResidual stenosisRestenotic lesionsMulticenter studyFemoropopliteal arteriesEndovascular SystemAngioplastyArteryClassification 2DissectionLesionsBalloonStenosisPatencyPatientsClinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent
Saito Y, Baumbach A, Wijns W, Xu B, Kelbæk H, Zheng M, Morel M, Anderson R, Schächinger V, Lansky A, Investigators T. Clinical outcomes of complex lesions treated with an abluminal groove‐filled biodegradable polymer sirolimus‐eluting stent and durable polymer everolimus‐eluting stent. Catheterization And Cardiovascular Interventions 2019, 96: 1023-1028. PMID: 31769161, DOI: 10.1002/ccd.28609.Peer-Reviewed Original ResearchConceptsHigh-risk patientsClinical outcomesComer studyI trialDurable polymer everolimus-eluting stentsTarget vessel myocardial infarctionSirolimus-eluting coronary stentYear clinical outcomesTarget lesion failureVessel myocardial infarctionLow-risk patientsWorse clinical outcomesEverolimus-eluting stentsHigh-risk groupLow-risk groupStrict eligibility criteriaFIREHAWK stentLesion failurePrimary endpointRandomized trialsMyocardial infarctionRisk groupsInclusion criteriaComplex lesionsXIENCE stentPredictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation
Krittanawong C, Kumar A, Wang Z, Johnson KW, Rastogi U, Narasimhan B, Kaplin S, Virk HUH, Baber U, Tang W, Lansky AJ, Stone GW. Predictors of In-Hospital Mortality after Transcatheter Aortic Valve Implantation. The American Journal Of Cardiology 2019, 125: 251-257. PMID: 31759517, DOI: 10.1016/j.amjcard.2019.10.014.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve implantationBaseline heart failureAortic valve implantationHeart failureAdditional independent predictorsHospital mortalityEjection fractionIndependent predictorsValve implantationPresence of HFReduced ejection fractionSevere aortic stenosisIn-Hospital MortalityPredictors of mortalityPotential baseline confoundersAortic valve stenosisICD-9 codesAbsence of depressionTAVI patientsHF patientsAortic stenosisValve stenosisLiver diseaseMultivariable analysisPatient selectionSafety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses
Ali ZA, Nef H, Escaned J, Werner N, Banning AP, Hill JM, De Bruyne B, Montorfano M, Lefevre T, Stone GW, Crowley A, Matsumura M, Maehara A, Lansky AJ, Fajadet J, Di Mario C. Safety and Effectiveness of Coronary Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Stenoses. Circulation Cardiovascular Interventions 2019, 12: e008434. PMID: 31553205, DOI: 10.1161/circinterventions.119.008434.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overCardiac CatheterizationCoronary AngiographyCoronary StenosisEuropeFemaleHumansLithotripsyMaleMiddle AgedPatient SafetyPercutaneous Coronary InterventionProspective StudiesRisk FactorsSeverity of Illness IndexStentsTime FactorsTomography, Optical CoherenceTreatment OutcomeUnited StatesVascular CalcificationConceptsSevere coronary artery calcificationCoronary artery calcificationMajor adverse cardiac eventsAdverse cardiac eventsPrimary end pointIntravascular lithotripsyOptical coherence tomographyCardiac eventsStent implantationPlaque fractureHospital major adverse cardiac eventsNon-Q-wave myocardial infarctionOptical coherence tomography substudyIndependent clinical events committeeCoherence tomographyDrug-eluting stent implantationEnd pointCoronary intravascular lithotripsyClinical events committeeHigh procedural successIndependent core laboratoryAcute luminal gainPost-approval studiesMechanism of actionCalcium fracture2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent
Xu B, Saito Y, Baumbach A, Kelbæk H, van Royen N, Zheng M, Morel MA, Knaapen P, Slagboom T, Johnson TW, Vlachojannis G, Arkenbout KE, Holmvang L, Janssens L, Ochala A, Brugaletta S, Naber CK, Anderson R, Rittger H, Berti S, Barbato E, Toth GG, Maillard L, Valina C, Buszman P, Thiele H, Schächinger V, Lansky A, Wijns W, Investigators T. 2-Year Clinical Outcomes of an Abluminal Groove–Filled Biodegradable-Polymer Sirolimus-Eluting Stent Compared With a Durable-Polymer Everolimus-Eluting Stent. JACC Cardiovascular Interventions 2019, 12: 1679-1687. PMID: 31129092, DOI: 10.1016/j.jcin.2019.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAbsorbable ImplantsAgedCardiovascular AgentsCoronary Artery DiseaseCoronary ThrombosisDrug-Eluting StentsDual Anti-Platelet TherapyEuropeEverolimusFemaleHumansMaleMiddle AgedPercutaneous Coronary InterventionPolymersProspective StudiesProsthesis DesignRisk FactorsSirolimusTime FactorsTreatment OutcomeConceptsTarget lesion failureXIENCE stentXience groupLesion failurePrimary endpointClinical outcomesIschemia-driven target lesion revascularizationTarget vessel myocardial infarctionProbable stent thrombosisTarget lesion revascularizationVessel myocardial infarctionLong-term outcomesDurable polymer everolimusBiodegradable Polymer SirolimusAbluminal grooveFIREHAWK stentLesion revascularizationCardiac deathComparable safetyStent thrombosisMyocardial infarctionClinical trialsEfficacy profileNoninferiority trialLandmark analysis